The Fred & Pamela Buffett Cancer Center is a recognized leader in cellular therapies such as stem cell transplants, bone marrow transplants and CAR T-cell therapy, treatments that harness the body’s own cells to fight cancer.
Kathy Folk never expected to become a medical pioneer. But 13 years after her cancer diagnosis, Folk made history as Nebraska’s first outpatient CAR T-cell therapy patient.
Jan Janisch-Hanzlik had been having strange symptoms for several years, was diagnosed with MS, and referred to Rana Zabad, MD. Dr. Zabad offered her a new option: enrollment in a first-of-its-kind clinical trial using allogeneic CAR T-cell therapy.
After more than four decades of infusing himself with the blood clotting factor his body can’t make, Chad Stevens decided it was time to try something new.
When the Nebraska Medicine Blood and Bone Marrow Transplant Program celebrated its 40th anniversary in 2023, Bruce Sheffield, MD, was there. Dr. Sheffield is one of the thousands of patients who have benefitted from the program’s success.
Maria Alvarran travels from Sioux City, Nebraska, every three months to visit the Fred & Pamela Buffett Cancer Center in Omaha, Nebraska. Alvarran is helping research be the best it can be. How? By bringing diversity to potential cancer therapies. Alvarran doesn’t speak English.
Our immune system is an unseen engine that is always idling, waiting to shift gears in the face of an infection. However, if the body’s immune transmission goes wrong, lymphoma may arise.
You’re about to leave the Nebraska Medicine website. The other site may collect information about your visit, including your IP address. Do you want to continue?